The Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Glycemic Control and Inappropriate Glucagon Secretion in Non-obese Japanese Patients With Type 2 Diabetes.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 08 Aug 2012 Actual initiation date (1 Jul 2012) added as reported by ClinicalTrials.gov.
- 31 Jul 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.